UGCG Antibodies

Santa Cruz Biotechnology features a diverse variety of UGCG monoclonal antibodies for investigating UDP-glucose ceramide glucosyltransferase (UGCG) in various biological processes. UGCG monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). UGCG is a key enzyme involved in the synthesis of glucosylceramide, a crucial component of cell membranes and a precursor for complex glycosphingolipids. UDP-glucose ceramide glucosyltransferase (UGCG) plays a significant role in cellular signaling, lipid metabolism, and maintaining cellular homeostasis. Research has shown that UDP-glucose ceramide glucosyltransferase (UGCG) dysregulation is linked to various diseases, including Gaucher disease and certain cancers. Scientists can explore UGCG expression patterns across different tissue types and cellular compartments using specific detection methods. Understanding UGCG function and regulation contributes to developing targeted therapeutic strategies. Multiple formats of UGCG monoclonal antibodies are available for diverse experimental applications. Santa Cruz Biotechnology monoclonal antibodies enable researchers to advance their understanding of UGCG biology and its implications in human health and disease.